<DOC>
	<DOCNO>NCT00393198</DOCNO>
	<brief_summary>The purpose study ass bleed pattern last 3 month first MIRENA® first year second MIRENA® use .</brief_summary>
	<brief_title>Bleeding Pattern User Satisfaction During Second Consecutive MIRENA® Contraception Treatment Menorrhagia</brief_title>
	<detailed_description>This study previously post Schering AG , Germany . Schering AG rename Bayer Schering Pharma AG , Germany.Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<criteria>Woman currently use MIRENA contraception menorrhagia duration use 4 year 3 month 4 year 9 month willingness continue method . Normal size uterus insertion , correspond sound measure 610 cm . Clinically normal cervical smear result within 12 precede month screen . Clinically normal breast examination finding . For patient &gt; /= 40 year screen , clinically normal mammography result within 12 precede month screen require . Menopausal symptoms impair patient 's quality life current estrogen therapy menopausal symptom . Known suspect pregnancy . Any distortion uterine cavity , include congenital acquire uterine anomaly fibroid distort uterine cavity . Current recurrent pelvic inflammatory disease . Abnormal uterine bleed unknown origin . Acute cervicitis vaginitis respond treatment . History , diagnose suspect genital malignancy ( exclude treat squamous cell carcinoma skin ) , untreated cervical dysplasia . Any active acute liver disease liver tumor .</criteria>
	<gender>Female</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Intrauterine System</keyword>
	<keyword>Contraception</keyword>
	<keyword>Menorrhagia</keyword>
</DOC>